

COMMON BID CUM APPLICATION FORM

BIO MEDICA LABORATORIES LIMITED - INITIAL PUBLIC ISSUE - NR

Registered Office: Plot No. 11B-11C, Sector-E, Sanwer Road, Industrial Area, Industrial Estate (Indore), Indore, Madhya Pradesh - 452015, India
Tel: +91 7314102751 Fax: N.A. Website: www.biomedica.co.in Email :companysecretary@biomedica.co.in
Company Secretary and Compliance Officer: Ms. Pratiksha Bhandari CIN: U24230MP2015PLC034576

FOR NON-RESIDENTS, INCLUDING ELIGIBLE NRIs, FPIs, FVCIs AND REGISTERED MULTI LATERAL AND BILATERAL DEVELOPMENT FINANCIAL INSTITUTIONS ETC. APPLYING ON A REPATRIATION BASIS



To,
The Board of Directors

BIO MEDICA LABORATORIES LIMITED

100% BOOK BUILT ISSUE

ISIN: INE1BKA01015

Bid cum
Application
Form No.

MEMBERS OF THE SYNDICATE STAMP & CODE		SUB-SYNDICATE MEMBER/ REGISTERED BROKER SCSB/CDP/RTA STAMP & CODE		1. NAME & CONTACT DETAILS OF SOLE / FIRST BIDDER	
				Mr./Ms./M/s. _____	
				Address _____	
SUB-BROKER'S / SUB-AGENT'S STAMP &		SCSB BRANCH STAMP & CODE		Email _____	
				Tel. No.(with STD code) / Mobile _____	
BANK BRANCH SERIAL NO.		SCSB SERIAL NO.		2. PAN OF SOLE / FIRST BIDDER	
3. BIDDER'S DEPOSITORY ACCOUNT DETAILS <input type="checkbox"/> NSDL <input type="checkbox"/> CDSL					

For NSDL enter 8 digit DP ID followed by 8 digit Client ID / For CDSL enter 16 digit Client ID

4. BID OPTIONS (ONLY INDIVIDUAL BIDDERS CAN BID AT "CUT-OFF")															5. CATEGORY		6. INVESTOR STATUS			
Bid Options	No. of Equity Shares Bid (In Figures) (Bids must be in multiples of 1,000 Equity Shares)								Price per Equity Share (₹) / "Cut-off" (Price in multiples of ₹ 1 only) (In Figures only)							"Cut-off" (Please ✓ tick)	<input type="checkbox"/> Individual Bidder	<input type="checkbox"/> Non-Institutional Bidder	<input type="checkbox"/> QIB	<input type="checkbox"/> Non-Resident Indian(s) (Repatriation basis - NRI) <input type="checkbox"/> Registered Bilateral and Multilateral Development Financial Institutions - RBM <input type="checkbox"/> Foreign Venture Capital Investor - FVCI <input type="checkbox"/> Foreign Portfolio Investor - FPI <input type="checkbox"/> All entities other than QIBs, Bodies Corporate and Individual - NOH <input type="checkbox"/> Other - OTH
									Bid Price			Retail Discount		Net Price						
	8	7	6	5	4	3	2	1	3	2	1	3	2	1						
Option 1																				
(OR) Option 2																				
(OR) Option 3																				

Please note that applications must be made in minimum of 2,000 Equity Shares and further multiples of 1,000 Equity Shares accordingly.

7. PAYMENT DETAILS [IN CAPITAL LETTERS]															PAYMENT OPTION : FULL PAYMENT <input checked="" type="checkbox"/>	
Amount blocked(₹ in figures) _____ (₹ in words) _____																
ASBA Bank A/c No. _____																
Bank Name & Branch _____																
OR																
UPI ID(Maximum 45 characters) _____																

I/WE (ON BEHALF OF JOINT BIDDERS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ AND UNDERSTOOD THE TERMS AND CONDITIONS OF THIS COMMON BID CUM APPLICATION FORM, THE ATTACHED ABBRIDGED PROSPECTUS AND THE GENERAL INFORMATION DOCUMENT ("GID") FOR INVESTING IN PUBLIC ISSUES AND HEREBY AGREE AND CONFIRM THE BIDDER'S UNDERTAKING AS GIVEN OVERLEAF. I/WE (ON BEHALF OF JOINT BIDDERS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ THE INSTRUCTIONS FOR FILING UP THE BID CUM APPLICATION FORM GIVEN OVERLEAF.

8A. SIGNATURE OF SOLE/ FIRST BIDDER		8B. SIGNATURE OF ASBA BANK ACCOUNT HOLDER(S) (AS PER BANK RECORDS)		MEMBERS OF THE SYNDICATE / SUB-SYNDICATE MEMBER / REGISTERED BROKER / SCSB / CDP / RTA / AGENT STAMP (Acknowledging upload of Bid in Stock Exchange system)	
		I/We authorise the SCSB to do all acts as are necessary to make the application in the Offer.			
		1) _____			
		2) _____			
		3) _____			
Date: _____, 2026					

TEAR HERE

BIO MEDICA LABORATORIES LIMITED		Acknowledgement Slip for Members of the Syndicate / Sub-Syndicate Member / Registered Broker / SCSB / CDP / RTA / Agent		Bid cum Application Form No.	
INITIAL PUBLIC ISSUE - NR					
DP ID / CL ID				PAN of Sole / First Bidder	
Amount blocked (₹ in figures)		ASBA Bank A/c No./UPI ID		Stamp & Signature of SCSB Branch	
Bank Name & Branch					
Received from Mr./Ms./M/s.					
Telephone / Mobile		Email			

TEAR HERE

BIO MEDICA LABORATORIES LIMITED INITIAL PUBLIC ISSUE - NR		Option 1	Option 2	Option 3	Stamp & Signature of Members of the Syndicate / Sub-Syndicate Member / Registered Broker / SCSB / CDP / RTA / Agent	Name of Sole / First Bidder
	No. of Equity Shares					
	Bid Price (₹)					
	Amount Blocked (₹ in figures)					
	ASBA Bank A/c No./UPI ID					
	Bank Name & Branch					
Important Note: Application made using third party UPI ID or ASBA Bank A/c are liable to be rejected.						Acknowledgement Slip for Bidder Bid cum Application Form No.

BIO MEDICA LABORATORIES LIMITED

1

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS DATED May13, 2026 (THE "RHP").YOU ARE ENCOURAGED TO READ GREATER DETAILS AVAILABLE IN THE RHP.

BIDDER'S UNDERTAKING AND CONFIRMATION FOR BID CUM APPLICATION FORM

(IN CASE OF A JOINT BID, THE CONFIRMATIONS, AUTHORISATIONS, UNDERTAKINGS AND REPRESENTATIONS MADE BY THE FIRST BIDDER WILL BE DEEMED TO HAVE BEEN MADE ON BEHALF OF ALL JOINT BIDDERS. THE FIRST BIDDER SHALL BE LIABLE FOR ALL THE OBLIGATIONS ARISING OUT OF THE ISSUE OF EQUITY SHARES.)

The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction. On the basis of the RHP filed with the Registrar of Companies, Gwalior (the "RoC") (if I am/we are in India) or the preliminary international wrap together with the RHP (the "Preliminary Offering Memorandum") (if I am/we are outside India), the General Information Document for Investing in Public Offerings ("GID") and having studied the attached details as per the Abridged Prospectus, I/we hereby apply for Allotment to me/us of the Equity Shares in the Issue up to my/our Bids for maximum number of Equity Shares at or above the Issue Price, to be discovered through the Book Building Process. I/we hereby confirm that I am/we are eligible person(s) to invest in the Issue in accordance with applicable laws. The amount payable on Bidding has been blocked in the ASBA Account with the relevant SCsB or the bank account linked with the UPI ID (in case of UPI Bidders using UPI Mechanism) as mentioned in this Bid cum Application Form, as the case may be. I/we agree to accept the Equity Shares Bid for, or such lesser number as may be Allotted to me/us subject to the terms of the RHP (if I am/we are in India), Preliminary Offering Memorandum (if I am/we are outside India), Abridged Prospectus, the GID, the Bid cum Application Form and other applicable laws. I/we undertake that I/we will sign all such other documents and do all such acts, if any, necessary on my/our part to enable me/us to be registered as the holder(s) of the Equity Shares which may be Allotted and to register my/our address as given in the Depository records and to place my/our name on the register of members of the Company. I/we acknowledge that in case of QIB Bidders, only the SCsBs (for Bids other than the Bids by Anchor Investors), and the BRLM and their affiliated Syndicate Member (only in the Specified Locations) have the right to reject Bids (including on technical grounds) at the time of acceptance of Bid cum Application Form provided that the reasons for rejecting the same shall be provided to such Bidder in writing, whereas it has a right to reject it from Non-Institutional Bidders and Individual Bidders based only on technical grounds and/or as specified in the Abridged Prospectus, GID and the RHP or the Preliminary Offering Memorandum, as applicable. I/we authorise the Company to make the necessary changes in this Bid cum Application Form and the RHP for filing of the Prospectus with the RoC without intimation to me/us and use this Bid cum Application Form as the application form for the purpose of the Issue. I/we confirm that I/we have read the RHP (if I am/we are in India) or the Preliminary Offering Memorandum (if I am/we are outside India). My / our investment decision is solely based on the RHP or the Preliminary Offering Memorandum, as applicable and the Prospectus or the Final Offering Memorandum, as applicable.

I/WE CONFIRM THAT: EITHER I am/we are Indian national(s) resident in India and I am/we are not applying for the said Equity Shares as nominees of any person resident outside India or foreign national(s) I am/we are Indian national(s) resident in India and I am/we are applying for the said Equity Shares as power of attorney holder(s) of non-resident Indian(s) as mentioned on non-repatriation basis OR I am/we are Indian national(s) resident outside India and I am/we are applying for the said Equity Shares on my/our own behalf through NRO account on non-repatriation basis, I/we represent, warrant, acknowledge and agree with the Company and the BRLM as follows: (A) I/we have read the RHP (if I am/we are in India) or the Preliminary Offering Memorandum (if I am/we are outside India) and that my/our investment decision is based solely on the RHP or the Preliminary Offering Memorandum, as applicable; (B) I/we have read and agree to the representations, warranties and agreements contained in the section "Other Regulatory and Statutory Disclosures-Disclaimer in respect of Jurisdiction" in the RHP (if I am/we are in India) or in the sections "Transfer Restrictions" and "Distribution and Solicitation Restrictions" of the Preliminary Offering Memorandum (if I am/we are outside India); (C) the Equity Shares offered in the Issue have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or the securities laws of any state of the United States and may not be offered or sold in the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable U.S. state securities laws and that the Equity Shares are being offered and sold only outside the United States in accordance with Regulation S under the Securities Act; (D) I was/we were outside of the United States at the time the offer of the Equity Shares was made to me/us and I am/we are outside the United States at the time I/we signed this Bid cum Application Form; (E) the Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and Bids may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction; (F) I am/we are purchasing the Equity Shares pursuant to the laws of the jurisdictions applicable to me/us; (G) I am/we are not an affiliate of the Company or a person acting on behalf of such affiliate; (H) if I/we are making an application to acquire any of the Equity Shares as fiduciary or agent for one or more investor accounts, I/we have sole investment discretion with respect to each such account and I/we have full power to make the foregoing representations, warranties, acknowledgments and agreements on behalf of each such account; and (i) if I/we are making an application to acquire any of the Equity Shares for one or more managed accounts, I am/we are authorized in writing by each such managed account to subscribe to the Equity Shares for each such managed account and to make (and I/we hereby make) the representations, warranties, acknowledgments and agreements herein for and on behalf of each such account, reading the reference to "I/we" to include such accounts.

FOR QIB BIDDERS: We confirm that the Bid size/maximum Equity Shares applied for by us does not exceed the relevant regulatory approvals/limits. We are not prohibited from accessing capital markets under any order/ruling/judgment of any regulatory, judicial or any other authority, including Securities and Exchange Board of India ("SEBI") or under the provisions of any law, regulation or statute.

Further: (1) In accordance with ASBA process provided in the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended ("SEBI ICDR Regulations") and as disclosed in the RHP or the Preliminary Offering Memorandum, as applicable, I/we authorise (a) the Members of the Syndicate (in Specified Locations only) or the Registered Brokers (at Broker Centres) or the SCsBs (at Designated SCsBs Branches) or the RTAs (at Designated RTA Locations) or the CDPs (at Designated CDP Locations), as the case may be, to do all acts as are necessary to make the application in the Offer, including uploading our Bid, blocking, unblocking of funds in the bank account of the applicant maintained with the SCsB as specified in the Bid cum Application Form or in the bank account of the Applicant linked with the UPI ID provided in the Bid cum Application Form, as the case may be, transfer of funds to the Public Issue Account on receipt of instruction from Registrar to the Issue or the Sponsor Bank, as the case may be, after finalisation of Basis of Allotment; and (b) the Registrar to the Issue or Sponsor Bank, as the case may be, to issue instruction to the SCsBs to unblock the funds in the specified bank account upon finalisation of the Basis of Allotment. 2) In case the amount available in the specified bank account is insufficient as per the highest Bid option, the SCsB/Registrar to the Issue shall reject the application. 3) I/we hereby authorise the Members of the Syndicate (in Specified Locations only) or the Registered Brokers (at Broker Centres) or the SCsBs (at Designated SCsBs Branches) or CDPs (at Designated CDP locations) or the RTAs (at Designated RTA locations), as the case may be, to make relevant revisions as may be required to be done in the Bid, in the event of a revision of the Price Band.

I/we hereby provide our consent to the Stock Exchanges I Sponsor Bank / NPCI / Registrar to the Issue for collecting, storing and using validating our PAN details from the bank account where my / our amount is blocked by the relevant SCsBs.

I/we acknowledge that as per exiting policy of the Government of India, OCBs cannot participate in the Offer. I am/we are not an OCB. For further details, see "Issue Procedure" and "Restriction on Foreign Ownership of Indian Securities" beginning on pages 311 and 346 respectively of the RHP.

INSTRUCTIONS FOR FILLING UP THE BID CUM APPLICATION FORM

- Name of sole/ First Bidder should be exactly the same as it appears in the Depository records. In case of joint Bids, only the name of the First Bidder (which should also be the first name in which the beneficiary account is held) should be provided in the Bid cum Application Form. The Bid means an "indication to make an offer" during the Bid/Issue period by a Bidder and not an offer.
- The First Bidder, should mention his/ her PAN Allotted under the Income Tax Act, 1961, DP ID, Client ID and UPI ID (as applicable). Except for Bids by or on behalf of the Central or State Government and the officials appointed by the courts and by investors who are exempt from the requirement of obtaining/ specifying their PAN for transacting in the securities market and by persons residing in the state of Sikkim, the Bidders, or in the case of Bid in joint names, the First Bidder (the first name under which the beneficiary account is held), should mention his/ her PAN Allotted under the Income Tax Act, 1961. Any Bid cum Application Form without the PAN is liable to be rejected other than as specified above. Investors must ensure that their PAN is linked with Aadhaar and are in compliance with Central Board of Direct Taxes ("CBDT") notification dated February 13, 2020 and press release dated June 25, 2021.
- Based on the PAN, DP ID and Client ID provided by the Bidders, the Registrar to the Issue will obtain Demographic Details registered with Depository Participants to be used, among other things, for Allotment, technical rejections or unblocking ASBA Account. Hence, Bidders are advised to immediately update any change in their Demographic Details as appearing on the records of the Depository Participant to ensure accuracy of records. Please note that failure to do so could result in failure in Allotment and delays in unblocking of ASBA Account at the Bidders, sole risk and neither the Members of the Syndicate nor the Registered Brokers nor the Registrar to the Issue nor RTAs/ CDPs nor the Company shall have any responsibility and undertake any liability for the same.
- Bid Lot and Price Band:** The face value of Equity Shares is ₹ 10/- each. The Price Band and the minimum Bid Lot size has been decided by the Company in consultation with the BRLM. The Price Band and Minimum Bid Lot Size have been advertised in all editions of Financial Express (a widely circulated English national daily newspaper) and all editions of Jansatta (a widely circulated Hindi national daily newspaper), all edition of Jansatta, being the regional language of Indore where our Registered Office is located, at least two (2) Working Days prior to the Bid/Issue Opening Date with the relevant financial ratios calculated at the Floor Price and at the Cap Price and have been made available to the NSE Limited for the purpose of uploading on its websites in accordance with SEBI ICDR Regulations. In case of revision of the Price Band, the Bid/Issue Period will be extended for at least three (3) additional Working Days after revision of Price Band subject to the Bid/Issue Period not exceeding a total of ten (10) Working Days. In case of force majeure, banking strike or similar circumstances, the Company may, for reasons to be recorded in writing, extend the Bid/Issue Period for a minimum of one (1) Working Days, subject to the Bid/Issue Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/Issue Period, if applicable, will be widely disseminated by notification to the Stock Exchanges, by issuing a press release and also by indicating the changes on the websites of the BRLM and on the terminals of the Members of the Syndicate and by intimation to Designated Intermediaries and the Sponsor Bank as applicable.
- Maximum and Minimum Bid Size:** In case of Individual Investors and Individual Shareholders the bid must be for two lots with minimum application size of above ₹ 2 lakhs. In case of Non-Institutional Bidders and QIB Bidders, the minimum Bid size shall be Such number of Equity Shares and in multiples of 1,000 Equity Shares. The maximum Bid by any investor should not exceed the investment limits prescribed for them by applicable laws and mentioned in the RHP or Preliminary Offering Memorandum, as applicable.
- Please tick category as applicable to ensure proper upload of Bid in Stock Exchange system.
- Please tick investor status as applicable. Please ensure investor Status is updated in your Depository records.
- Cheques/Demand Draft/Cash/stock invest/money orders/postal orders will not be accepted.** Eligible NRIs bidding on a non-repatriation basis by using the Resident Bid cum Application Form are required to authorise the SCsB to confirm or accept the UPI Mandate Request (in case of UPI Bidders Bidding through the UPI Mechanism), block their Non-Resident Ordinary (NRO) Accounts for the full Bid Amount, at the time of the submission of the Bid cum Application Form. All Bidders including the Eligible NRIs Bidding on a non-repatriation basis can obtain the Bid cum Application Form from the Registered and Corporate Office of the Company or from any of the Members of the Syndicate or CDPs or RTAs or Registered Brokers from the Bidding Centers. In accordance with applicable law and SEBI UPI Circulars, Bidders to please ensure that SCsB where the ASBA Account is maintained has notified at least one branch in the location where Bid cum Application Forms will be deposited by Designated Intermediaries.
- Please note that application made using third party UPI ID or third party ASBA Bank Account are liable to be rejected.
 - QIBs cannot use UPI Mechanism to apply. UPI Bidders applying up to ₹5,00,000 shall apply through UPI mode as per NPCI vide circular reference no. NPCI/UI/OC No. 127/2021-22 dated December 09, 2021 read with SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/45 dated April 5, 2022.
 - UPI Bidders using UPI Mechanism:**
 - Please ensure that your bank is offering UPI facility for public offers.
 - Please mention UPI ID clearly in CAPITAL LETTERS only.
 - Ensure that the: (a) bank where the bank account linked to their UPI ID is maintained; and (b) Bidders Bidding using the UPI Mechanism may apply through the SCsBs and mobile applications whose names appears on the website of the SEBI (<https://www.sebi.gov.in/sebiweb/other/Action.do?do=recognisedPr=yes&intmid=40>) and (<https://www.sebi.gov.in/sebiweb/other/Action.do?do=recognisedPr=yes&intmid=40>) respectively, as updated from time to time.
 - Eligible NRIs applying in the Issue through the UPI Mechanism, are advised to ensure with the relevant bank where their account is UPI linked prior to submitting their Bid cum Application Form.
 - UPI ID cannot exceed 45 characters.
 - Please ensure that you are using your UPI ID only and not the UPI ID of any third party.
 - UPI Bidders Bidding using the UPI Mechanism shall ensure that details of the Bid are reviewed and verified by opening the attachment in the UPI Mandate Request and then proceed to authorise the UPI Mandate Request using his/her UPI PIN. For further details, see "Issue Procedure" on page 311 of the RHP.
- Only the First Bidder is required to sign the Bid cum Application Form /Revision Form. Thumb impressions and signatures other than in the languages specified in the Eighth Schedule to the Constitution of India must be attested by a Magistrate or a Notary Public or a Special Executive Magistrate under official seal. Signature of ASBA Account holder is mandatory. If the First Bidder is not the account holder, ensure that the Bid cum Application Form is signed by the account holder. Necessary revisions in the Bidders' undertaking and instructions will be required depending upon the jurisdiction in which the sale of shares is proposed.
- Other Instructions:** a. Bids must be made only in the prescribed Bid cum Application Form. b. Bids must be completed in full, in BLOCK LETTERS in ENGLISH. Bidders should note that the Members of the Syndicate, Registered Broker, CDPs, RTAs, and/or SCsBs will not be liable for errors in data entry due to incomplete or illegible Bid cum Application Forms; and c. Ensure that all applicable documents in support of the Bid are attached with the Bid cum Application Form.
- The Bidders may note that in case the DP ID, Client ID and PAN mentioned in the Bid cum Application Form and entered into the electronic bidding systems of the Stock Exchanges do not match with the DP ID, Client ID and PAN available in the Depository database, the Bid cum Application Form is liable to be rejected. Investors must ensure that their PAN is linked with Aadhaar and are in compliance with CBDT notification dated February 13, 2020 and press release dated June 25, 2021. You may send the RHP and the Prospectus (if you are in India) or the Preliminary Offering Memorandum and the Final Offering Memorandum (if you are outside India) either in physical form or electronic form or both. You shall not distribute or forward this documents and these documents are subject to the disclaimers and restrictions contained in or accompanying in it.
- The Equity Shares have not been and will not be registered under the Securities Act or any state securities laws in the United States, and unless so registered, and may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulations and the applicable laws of each jurisdictions where such offers and sales are made.
- This Bid cum Application Form is being offered to you on the basis that you (i) confirm that the representations, warranties, agreements and acknowledgement set out in "Other Regulatory and Statutory Disclosures" and "Issue Procedure" on pages 287 and 311 respectively of the RHP and (ii) agree to abide by (1) this Bid cum Application Form and (2) the RHP (if you are in India) or the Preliminary Offering Memorandum (if you are outside India) together with the terms and conditions contained therein.

Note: Terms used but not defined herein shall have the meaning assigned to such terms in the RHP or the Preliminary Offering Memorandum, as applicable. For detailed instructions for filling the various fields of this Bid cum Application Form, please refer to the GID, which is also available on the respective websites of the BRLM and the Stock Exchanges

TEAR HERE

COMPANY CONTACT DETAILS		REGISTRAR TO THE ISSUE CONTACT DETAILS
BIO MEDICA LABORATORIES LIMITED		SKYLINE FINANCIAL SERVICES PRIVATE LIMITED
Registered Office: Plot No. 11B-11C, Sector-E, Sanwer Road, Industrial Area, Industrial Estate (Indore), Indore, Madhya Pradesh – 452015, India		Address: D-153 A, 1st Floor, Okhla Industrial Area, Phase-I, New Delhi-110020
Tel: +91- 7314102751		Telephone: +91-11-40450193-97
Fax: N.A.		Email: ipo@skylinert.com
Company Secretary and Compliance Officer: Ms. Pratiksha Bhandari		Website: www.skylinert.com
Website: www.biomedica.co.in		Contact Person: Mr. Anuj Rana
E-mail: companysecretary@biomedica.co.in		SEBI Registration Number: INR000003241
CIN: U24230MP2015PLC034576		CIN: U67100DL2010PTC208725



Please scan this QR Code to view the RHP and Abridged Prospectus



Bio Medica Laboratories
BIO MEDICA LABORATORIES LIMITED
(Formerly known as Bio Medica Laboratories Private Limited)
CIN: U24230MP2015PLC034576

Red Herring Prospectus
Dated: May 13, 2026
100% Book Building Offer

Please read Section 26 and 32 of Companies Act, 2013

REGISTERED OFFICE	CORPORATE OFFICE	CONTACT PERSON	EMAIL & TELEPHONE	WEBSITE
Plot No. 11B-11C, Sector-E, Sanwer Road, Industrial Area, Industrial Estate (Indore), Indore, Madhya Pradesh – 452015, India	N.A.	Ms. Pratiksha Bhandari Company Secretary & Compliance Officer	companysecretary@biomedica.co.in & +91 7314102751	www.biomedica.co.in

NAME OF THE PROMOTERS OF THE COMPANY

MR. MUKESH MEHTA AND MR. PRADEEP MEHTA

DETAILS OF OFFER TO PUBLIC, PROMOTERS/ SELLING SHAREHOLDERS

Type	Fresh Issue Size (by No. of shares)	OFS** Size (by No. of shares)	Total Issue Size (by No. of shares)	Eligibility & Share Reservation among NII & RII
Fresh Issue and Offer for Sale	Up to 33,95,000 Equity Shares of face value of ₹ 10.00/- each aggregating up to Rs [●] Lakhs.	Up to 3,77,000 Equity Shares of face value of ₹ 10.00/- each aggregating up to Rs [●] Lakhs.	Up to 37,72,000* Equity Shares of face value of ₹ 10.00/- each aggregating up to Rs [●] Lakhs.	The Offer is being made pursuant to Regulation 229(2) of SEBI (ICDR) Regulations. For details of Share reservation among QIBs, NIIs and RIIs, see “Issue Structure” beginning on page 347

*The Number of Shares to be issued has been revised for the adjustment of Lot Size.

**OFS: Offer for Sale

Details of OFS by Promoter(s)/ Promoter Group/ Other Selling Shareholders (upto maximum of 10 shareholders)

Name	Type	No. of shares offered/ Amount in Rs.	WACA in Rs. Per Equity Shares
Mukesh Mehta	Promoter Selling Shareholder	1,88,500 Equity Shares of face value of Rs. 10/- each	Nil
Pradeep Mehta	Promoter Selling Shareholder	1,88,500 Equity Shares of face value of Rs. 10/- each	Nil

As certified by M/s Vijay K Jain & Associates, Chartered Accountants, by way of their certificate dated May 08, 2026.

P: Promoter, PG: Promoter Group, OSS: Other Selling Shareholders, WACA: Weighted Average Cost of Acquisition on fully diluted basis

RISKS IN RELATION TO THE FIRST ISSUE

This being the first public issue of our Company, there has been no formal market for the Equity Shares. The face value of our Equity Shares is Rs.10 each and the Floor Price and Cap Price are [●] times and [●] times of the face value of the Equity Shares, respectively. The Floor Price, Cap Price and Issue Price (determined and justified by our Company in consultation with the Book Running Lead Manager as stated in “Basis for Issue Price” on page 110 of this Red Herring Prospectus) should not be taken to be indicative of the market price of the Equity Shares after the Equity Shares are listed. No assurance can be given regarding an active or sustained trading in the Equity Shares or regarding the price at which the Equity Shares will be traded after listing.

GENERAL RISK

Investments in Equity and Equity related securities involve a degree of risk and investors should not invest any funds in this issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Issue. For taking an investment decision, investors must rely on their own examination of our Company and the Issue including the risks involved. The Equity Shares issued in the Issue have not been recommended or approved by the Securities and Exchange Board of India (“SEBI”), nor does SEBI guarantee the accuracy or adequacy of the Red Herring Prospectus. Specific attention of the investors is invited to the section “Risk Factors” beginning on page 21 of this Red Herring Prospectus.

ISSUER’S ABSOLUTE RESPONSIBILITY

Our Company, having made all reasonable inquiries, accepts responsibility for and confirms that this Red Herring Prospectus contains all information with regard to our Company and the Issue which is material in the context of this Issue, that the information contained in this Red Herring Prospectus is true and correct in all material aspects and is not misleading in any material respect, that the opinions and intentions expressed herein are honestly held and that there are no other facts, the omission of which make this Red Herring Prospectus as a whole or any of such information or the expression of any such opinions or intentions misleading in any material respect.

LISTING

The Equity Shares of our Company offered through this Red Herring Prospectus are proposed to be listed on the Emerge Platform of National Stock Exchange of India Limited in terms of the Chapter IX of the SEBI (ICDR) Regulations, 2018 as amended from time to time. Our Company has received an approval letter dated 19th November, 2025 from National Stock Exchange of India Limited for using its name in the Red Herring Prospectus for listing of our shares on the Emerge Platform of National Stock Exchange of India Limited. For the purpose of this Issue, National Stock Exchange of India Limited shall be the Designated Stock Exchange.

BOOK RUNNING LEAD MANAGER TO THE ISSUE

REGISTRAR TO THE ISSUE

Narnolia®

NARNOLIA FINANCIAL SERVICES LIMITED

Address: 201, 2nd Floor, Marble Arch, 236 B A.J.C Bose Road, Kolkata, West Bengal- 700020, India

Telephone: 033- 40501500

Email: ipo@narnolia.com

Website: www.narnolia.com

Contact Person: Mr. Rajveer Singh

SEBI Registration Number: INM000010791

CIN: U51909WB1995PLC072876

Skyline
Financial Services Pvt. Ltd.

SKYLINE FINANCIAL SERVICES PRIVATE LIMITED

Address: D-153 A, 1st Floor, Okhla Industrial Area, Phase - I, New Delhi-110020

Telephone: +91-11-40450193-97

Email: ipo@skylinerta.com

Website: www.skylinerta.com

Contact Person: Mr. Anuj Rana

SEBI Registration Number: INR000003241

CIN: U74899DL1995PTC071324

BID/ISSUE PERIOD

Anchor Bid Opens on ⁽¹⁾: NA

Bid/ Issue Open on: May 21, 2026

Bid/ Issue Closes on ⁽²⁾⁽³⁾: May 25, 2026


****Subject to Finalization of Basis of Allotment**

⁽¹⁾ Our Company in consultation with the BRLM, may consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bidding Date shall be one working day prior to the Issue Opening Date.

⁽²⁾ Our Company may, in consultation with the Book Running Lead Manager, consider closing the Bid/Issue Period for QIBs one Working Day prior to the Bid/Issue Closing Date in accordance with the SEBI ICDR Regulations.

⁽³⁾ UPI mandate end time and date shall be at 5:00 pm on the Bid/Issue Closing Date.

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS

	<p>The following is a general summary of certain disclosures in the Red Herring Prospectus and the terms of the Offer and is not exhaustive, nor does it purport to contain a summary of all the disclosures in the Red Herring Prospectus or all details relevant to prospective investors. This summary should be read in conjunction with, and is qualified in its entirety by, the more detailed information appearing elsewhere in the Red Herring Prospectus, which is available at the websites of National Stock Exchange of India Limited the Company at www.biomedica.co.in and the BRLM at www.narnolia.com</p> <p>References below to page numbers are to page numbers of the Red Herring Prospectus dated May 13, 2026. Unless otherwise specified all capitalised terms used herein and not specifically defined bear the same meaning as ascribed to them in the Red Herring Prospectus.</p>
<p>Please scan this QR code to view the Red Herring Prospectus and the Abridged Prospectus</p>	

1. Summary of the primary business

Our Company is engaged in the manufacturing of Pharmaceutical Parenteral Formulations. We manufacture generic drugs in the form of injectables namely Liquid Injections and Dry Powder Injections. These injectables are available in both single dose and multi dose forms, catering both human and veterinary needs. Our products address a wide range of medical needs and preferences.

Our Company operates on a B2B business model through contract manufacturing and does not deal directly with the end users. Our company manufacture formulations for various companies according to their specific requirements and specifications for the type of formulation needed. Additionally, we enter into agreements with them, allowing their name and address to be displayed on the packaging as "Technical Collaborator" or "marketed by" alongside our Company's name as the manufacturer.

a. Business Overview - Products and Services

Our Company is involved in the manufacturing of pharmaceutical formulations, in the form of Liquid Injections and Dry Powder Injections. These injectables are available in various packaging forms, including ampoules and vials, in both single and multi-dosage catering both human and veterinary needs. Our products address a wide range of medical needs and preferences both domestically as well as exported through Merchant Exporter.

b. Industries Served and Typical Customers

Our Company operates in Pharmaceutical Sector, operating on a B2B business model through contract manufacturing and does not deal directly with the end users. Our company manufacture formulations for various companies according to their specific requirements and specifications for the type of formulation needed. Additionally, we enter into agreements with them, allowing their name and address to be displayed on the packaging as "Technical Collaborator" or "marketed by" alongside our Company's name as the manufacturer.

c. Segment Reporting and Revenue Contribution

S. No.	Source of Revenue	Description of Services
1.	Sale of Manufactured goods	Revenue generated from sale of Liquid and Dry Powder Injectables produced by our company.
2.	Sale of Trading goods	Revenue generated through the trading of raw materials, including base chemicals used in the production process and Tablet and packing material.

d. Key Geographies

The Company's operations are predominantly concentrated in the domestic market, with 99.62% of its revenue derived from India. It has established a pan-India presence, with a strong focus on key regions in Western and

Northern India, including Maharashtra, Madhya Pradesh, and Uttarakhand. Internationally, the Company generates a portion of its export revenue from Afghanistan.

e. Revenue Concentration Among Top 5 Customers

Particulars	For the period ended November 30 th 2025	Financial Year 2025	Financial Year 2024	Financial Year 2023
<i>Top 1 (one) customers</i>	872.35	1,205.29	122.98	144.89
<i>% of revenue from operations</i>	30.56%	31.56%	8.06%	8.93%
<i>Top 5 (five) customers</i>	1929.32	2,373.26	506	557.92
<i>% of revenue from operations</i>	67.59%	62.14%	33.17%	34.39%

f. Key Facilities

The key facilities of the company include its Registered Office and Manufacturing Unit situated at:

1. Plot No. 11-C, Sector E, Sanwer Road, Industrial Area, Indore - 452015, Madhya Pradesh, India
2. Plot No. 11-B, Sector E, Sanwer Road, Industrial Area, Indore - 452015, Madhya Pradesh, India
3. 254, Sector F, Industrial Area, Sanwer Road, Indore - 452015, Madhya Pradesh, India

g. Business Strengths and Strategies

Strengths

The Company is driven by experienced promoters, management and employees, led by Mr. Pradeep Mehta and Mr. Mukesh Mehta with over 37 years of industry experience. Its strong quality assurance is supported by GLP and GMP certifications and an in-house quality control system. The Company's multi-product capability and diversified product portfolio enables manufacturing of 71 formulations across generic, branded, and OTC segments. Further, established client relationships ensure consistent orders and support business growth, while a low attrition rate of employees reflects workforce stability and effective talent retention.

Strategies

The Company plans to expand and upgrade its manufacturing facilities by installing advanced plant and machinery and aligning infrastructure with WHO standards. This will help by the company to meet the rising demands in the pharmaceuticals injectable sector by enhancing production capacity, improving utilization, and increasing operational efficiency, particularly in the injectable segment.

2. Summary of the Industry (Source: Infomerics Report)

India's pharmaceutical industry is one of the most significant contributors to the national economy and a key player in the global healthcare landscape. The country ranks third globally in pharmaceutical production by volume and 14th by value and is widely recognized as the "Pharmacy of the World" owing to its large-scale production and export of affordable, high- quality generic medicines and vaccines.

India is the largest provider of generic drugs globally, accounting for approximately 20% of the global supply by volume and contributes over 60% of the global vaccine demand. As of 2024, India is home to over 3,000 pharmaceutical companies and more than 10,000 manufacturing facilities, including the highest number of USFDA-compliant plants outside the United States. This has positioned the country as a critical part of the global pharmaceutical supply chain, especially for regulated markets such as the United States, European Union, and Japan.

For further details, please refer to the chapter titled "Industry Overview" on page 123 of the Red Herring Prospectus.

3. Promoters

The promoters of our Company are Mr. Pradeep Mehta and Mr. Mukesh Mehta.

Mr. Pradeep Mehta is the Promoter and Managing Director of our Company. He is a founding member of the Company and was appointed as Director since the incorporation and designated as managing director of our Company on October 28, 2024. He completed his higher secondary education in the year 2005. Since 2015 he has been serving as a Whole Time Director of Bio Medica Laboratories Limited, where he is responsible for the growth, innovation and development of the company's strategies and business. He has more than 19 years of experience in the pharmaceutical sector.

Mr. Mukesh Mehta is the Promoter and Whole Time Director of our company. He is a founding member of the Company and was appointed as Director since the incorporation and designated as Whole Time Director of our Company on October 28, 2024. He completed his higher secondary education in the year 2006 and has more than 18 years of experience in the pharmaceutical sector. Since 2015 he has been serving as a Whole Time Director of Bio Medica Laboratories Limited, and looks after the overall operations, business development, marketing and sales of our company.

For further information, see “*Our Promoters*” beginning on page 228 of the Red Herring Prospectus.

4. Objects of the Offer

Our Company proposes to utilize the funds which are being raised towards funding the following objects and achieve the benefits of listing on the Emerge Platform of NSE.

Sr. No	Object of the Issue	Details of Utilisation
1	To meet out the Repayment of Loan;	Our Company has entered into various financing arrangements with bank. The loan facilities entered into by our Company include borrowings in the form of term loans and fund-based facilities. Our Company proposes to utilise an estimated amount of Rs. 650.00 Lakhs from the Net Proceeds as confirmed by the Statutory and Peer Review Auditor M/s Vijay K Jain & Associates, Chartered Accountants, vide Certificate dated May 08, 2026, towards full or partial repayment or prepayment of certain borrowing availed by our Company from bank.
2	Enhancement of the existing production capabilities by setting up of new manufacturing facility at the existing Manufacturing Unit II.	Our Company is engaged in the of manufacturing of Pharmaceutical Parenteral Formulations. We manufacture generic drugs in the form of injectables namely Liquid Injections and Dry Powder Injections. These injectables are available in both single dose and multi dose forms, catering both human and veterinary needs. Our products address a wide range of medical needs and preferences. Our company intends to deploy Net Proceeds from the issue aggregating to Rs. 2,850.00 Lakhs to meet out the Civil Construction Expenditure and Purchase of Plant & Machinery of our company for expanding our business operations. This expansion will help increase operational capacity and enhance business performance.
3	General Corporate Purposes	Our Company intends to deploy the balance Net Proceeds aggregating Rs. [●] Lakh for General Corporate Purposes subject to such utilization not exceeding 15% of the Gross Proceeds or Rs. 10 crores, whichever is lower, in compliance with the SEBI Regulations and circular issued thereafter, including but not limited or restricted to, strategic initiatives, strengthening our marketing network & capability, meeting exigencies, brand building exercises in order to strengthen our operations. Our management, in accordance with the policies of our Board, will have flexibility in utilizing the proceeds earmarked for General Corporate Purposes.

For further information, see “*Objects of the Issue*” beginning on page 88 of the Red Herring Prospectus.

5. Pre-Offer and Post-Offer shareholding of our Promoters, members of the Promoter Group and top 10 Shareholders

The aggregate shareholding, of each of the Promoters, members of our Promoter Group and top 10 Shareholders (other than our Promoters and members of our Promoter Group) is set out below:

S.No.	Pre-Issue shareholding as at the date of Red Herring Prospectus			Post-Offer shareholding as at date of Allotment*			
	Name of the shareholder	Number of Equity Shares	Share Holding (in %)	At the lower end of the price band (₹ 132)		At the upper end of the price band (₹ 139)	
				Number of Equity Shares	Shareholding (in %)	Number of Equity Shares	Shareholding (in %)
Promoters							
1.	Mukesh Mehta	44,44,816	48.42%	42,56,316	33.85%	42,56,316	33.85%
2.	Pradeep Mehta	44,44,725	48.42%	42,56,225	33.85%	42,56,225	33.85%
Total - A		88,89,541	96.84%	85,12,541	67.69%	85,12,541	67.69%
Member of our Promoter Group							
3.	Tara Mehta	92	Negligible	92	Negligible	92	Negligible
4.	Lokesh Jain	92	Negligible	92	Negligible	92	Negligible
5.	Garima Mehta	92	Negligible	92	Negligible	92	Negligible
6.	Anju Mehta	92	Negligible	92	Negligible	92	Negligible
Total - B		368	Negligible	368	Negligible	368	Negligible
Public Shareholders							
5.	Babu Mathew	92	Negligible	92	Negligible	92	Negligible
6.	Tiger Strategies Fund -I	2,90,000	3.16%	2,90,000	3.16%	2,90,000	3.16%
7.	IPO	-	-	37,72,000	30.00%	37,72,000	30.00%
Total-C		2,90,092	3.16%	40,62,092	32.30%	40,62,092	32.30%
Total A+B+C		91,80,001	100.00%	1,25,75,001	100.00%	1,25,75,001	100.00%

*Based on the Issue price of ₹ [●] and subject to finalization of the basis of allotment

Notes:

1) Includes all options that have been exercised until date of prospectus and any transfers of equity shares by existing shareholders after the date of the pre-issue and price band advertisements until date of prospectus.

2) Based on the Issue price of ₹ [●] and subject to finalization of the basis of allotment.

For further details, see “Capital Structure” beginning on page 72 of the Red Herring Prospectus

6. Summary of Restated Financial Information

The following details of selected financial information are derived from the Restated Financial Information for the period ended November 30, 2025 and for the Financial Years ended March 31, 2025, March 31, 2024 and March 31, 2023.

(Amount in Lakhs)

Particulars	As at November 30, 2025	As at March 31, 2025	As at March 31, 2024	As at March 31, 2023
Equity Share Capital	918.00	918.00	10.00	10.00
Net Worth	1,711.61	1,473.30	493.81	243.95
Revenue from Operations	2,854.69	3,819.52	1,524.94	1,622.82
EBITDA	1,344.72	1,521.33	563.13	169.89
Profit after Tax	866.39	979.49	249.87	33.35
Basic Earning Per Share	9.44	10.67	2.72	0.36
Diluted Earning Per Share	9.44	10.67	2.72	0.36

Return on Net Worth	54.41%	99.59%	67.74%	13.92%
Net Asset Value per Share	18.64	16.05	493.81	243.95
Total Borrowings	3,816.82	1,501.44	1,048.99	960.67
Net Cash Generated from operating activities	(575.71)	(367.17)	162.41	229.31
Net cash generated from / (used in) investing activities	(1,609.10)	33.88	(153.75)	(168.97)
Net cash generated from / (used in) financing activities	2,197.89	332.94	(8.25)	(212.53)

For further details, see “*Management’s Discussion and Analysis of Financial Condition and Results of Operations*”, “*Basis for Offer Price*” and “*Restated Financial Information*” beginning on pages 245, 110 and 243, respectively of the Red Herring Prospectus

7. Summary of Key Performance Indicators

Details of our KPIs for the period ended November 30, 2025 and for the Financial Years ended March 31, 2025, March 31, 2024 and March 31, 2023 are set out as below:

1. Key metrics like revenue growth, EBIDTA Margin, PAT Margin and few balance sheet ratio are monitored on a periodic basis for evaluating the overall performance of our Company.

KPI indicators

(Amount in Lakhs, except EPS, % and ratios)

Particulars	For the period ended November 30, 2025	Financial Year ended March 31st, 2025	Financial Year ended March 31st, 2024	Financial Year ended March 31st, 2023
Revenue from operations ⁽¹⁾	2,854.69	3,819.52	1,524.94	1,622.82
Growth in Revenue from Operations (%) ⁽²⁾	-	150.47%	(6.03) %	-
EBITDA ⁽³⁾	1,344.72	1,521.33	563.13	169.89
EBITDA (%) Margin ⁽⁴⁾	47.11%	39.83%	36.93%	10.47%
EBITDA Growth Period on Period ⁽⁵⁾	-	170.16%	231.47%	-
ROCE (%) ⁽⁶⁾	23.24%	48.20%	29.92%	10.16%
Current Ratio ⁽⁷⁾	1.52	1.83	1.61	0.89
Operating Cash flow ⁽⁸⁾	(575.71)	(367.17)	162.41	229.31
PAT ⁽⁹⁾	866.39	979.49	249.87	33.35
ROE/ RoNW ⁽¹⁰⁾	54.41%	99.59%	67.74%	13.92%
EPS ⁽¹¹⁾	9.44	10.67	2.72	0.36

Notes:

⁽¹⁾ Revenue from operations is the total revenue generated by our Company.

⁽²⁾ Growth in Revenue in percentage, Year on Year

⁽³⁾ EBITDA is calculated as Profit before tax + Depreciation + Interest Expenses – Other Income

⁽⁴⁾ EBITDA Margin’ is calculated as EBITDA divided by Revenue from Operations

⁽⁵⁾ EBITDA Growth Rate Year on Year in Percentage

⁽⁶⁾ ROCE: Return on Capital Employed is calculated as Earning for debt service divided by capital employed, which is defined as shareholders’ equity plus long term debt+ short term debt.

⁽⁷⁾ Current Ratio: Current Asset over Current Liabilities

⁽⁸⁾ Operating Cash Flow: Net cash inflow from operating activities.

⁽⁹⁾ PAT is mentioned as PAT for the period

⁽¹⁰⁾ ROE/RoNW is calculated PAT divided by average shareholders' equity

⁽¹¹⁾ EPS is mentioned as PAT divided by weighted average share outstanding taking after bonus impact.

KPI	Explanation
Revenue from operation	Revenue from Operations is used by our management to track the revenue profile of the business and in turn helps to assess the overall financial performance of our Company and volume of our business.
Revenue Growth Rate %	Revenue Growth rate informs the management of annual growth rate in revenue of the company in consideration to previous period
EBITDA	EBITDA provides information regarding the operational efficiency of the business
EBITDA Margin (%)	EBITDA Margin (%) is an indicator of the operational profitability and financial performance of our business
EBITDA Growth Rate %	EBITDA Growth Rate informs the management of annual growth rate in EBITDA of company in consideration to previous period
ROCE %	ROCE provides how efficiently our Company generates earnings from the capital employed in the business.
Current Ratio	Current ratio indicate the company's ability to bear its short-term obligations
Operating Cash Flow	Operating cash flow shows whether the company is able to generate cash from day-to-day business
PAT	Profit after Tax is an indicator which determine the actual earning available to equity shareholders
ROE/RoNW	It is an indicator which shows how much company is generating from its available shareholders' funds
EPS	Earning per shares is the company's earnings available of one share of the Company for the period

2. GAAP Financial Measures

GAAP Financial measures are numerical measures which are disclosed by the issuer company in accordance with the Generally Accepted Accounting Principles (GAAP) applicable for the issuer company i.e., measures disclosed in accordance with Indian Accounting Standards ("Ind AS") or Accounting Standards ("AS") notified in accordance with Section 133 of the Companies Act, 2013, as amended (the "Act"). These measures are generally disclosed in the financial statements of the issuer company.

On the basis of Financial statements.

(Amount in Lakhs)

Particulars	Financial Year ended			
	November 30 th , 2025	March 31st, 2025	March 31st, 2024	March 31st, 2023
Revenue from operations	2,854.69	3,819.52	1,524.94	1,622.82
Profit after tax	866.39	979.49	249.87	33.35
Cash flow from operating activities	(575.71)	(367.17)	162.41	229.31
Cash Flow from investing activities	(1,609.10)	33.88	(153.75)	(168.97)

Cash Flow from financing activities	2,197.89	332.94	(8.25)	(212.53)
Net Change in Cash and cash equivalents	13.08	(0.35)	0.41	(152.20)

3. Non- GAAP Financial measures

Non-GAAP Financial measures are numerical measures of the Technical Guide on Disclosure and Reporting of KPIs issuer company's historical financial performance, financial position, or cash flows that:

- Exclude amounts, or are subject to adjustments that have the effect of excluding amounts, that are included in the most directly comparable measures calculated and presented in accordance with GAAP in the financial statements of the issuer company; or
- Include amounts or are subject to adjustments that have the effect of including amounts, that are excluded from the most directly comparable measures so calculated and presented. Such adjustment items should be based on the audited line items only, which are included in the financial statements. These Non-GAAP Financial measures are items which are not defined under Ind AS or AS, as applicable. Generally, if the issuer company takes a commonly understood or defined GAAP amount and removes or adds a component of that amount that is also presented in the financial statements, the resulting amount is considered a Non-GAAP Financial measure. As a simplified example, if the issuer company discloses net income less restructuring charges and loss on debt extinguishment (having determined all amounts in accordance with GAAP), the resulting performance amount, which may be labelled "Adjusted Net Income," is a Non-GAAP Financial measure.

On the basis of Restated financial statements.

(Amount in Lakhs, except %)

Particulars	For the period ended November 30, 2025	Financial Year ended March 31, 2025	Financial Year ended March 31, 2024	Financial Year ended March 31, 2023
EBITDA	1,344.72	1,521.33	563.13	169.89
EBITDA Margin	47.11%	39.83%	36.93%	10.47%
Working Capital	1,625.86	1,409.69	399.58	(109.14)
PAT Margin	30.35%	25.64%	16.39%	2.06%
Net worth	1,711.61	1,473.30	493.81	243.95

Apart from the above, Ministry of Corporate Affairs (MCA), vide its notification dated March 24, 2021, has issued certain amendments to the Schedule III to the Act. Pursuant to these amendments, the below ratios are also required to be presented in the financial statements of the companies:

On the basis of Restated financial statements.

Particulars	For the period ended November 30 th , 2025	Financial Year ended March 31 st , 2025	Financial Year ended March 31 st , 2024	Financial Year ended March 31 st , 2023
Current ratio	1.52	1.83	1.61	0.89
Debt-equity ratio	2.23	1.02	2.12	3.94
Debt service coverage ratio	0.44	1.27	1.24	0.28
Inventory Turnover Ratio	1.30	3.00	2.71	5.21
Trade receivables turnover ratio	2.97	11.87	4.76	3.41
Trade payables turnover ratio	5.61	10.54	3.40	3.57

Net capital turnover ratio	1.88	4.22	10.50	(17.80)
Net profit ratio	30.35%	25.64%	16.39%	2.06%
Return on equity ratio	54.41%	99.59%	67.74%	13.92%
Return on capital employed	23.24%	48.20%	29.92%	10.16%

Ratio	Explanation
Current Ratio	Current Assets divided by Current Liabilities
Debt-equity ratio	Total debt (including current maturities of long-term borrowings) divided by Net worth
Debt service coverage ratio	Earnings Available for Debt Service / Debt Service
Inventory Turnover Ratio	Revenue from operations divided by Average Inventory
Trade receivables turnover ratio	Revenue from operations by Average Accounts Receivables
Trade payables turnover ratio	Total purchases divided by Average trade payables
Net capital turnover ratio	Revenue from Operations divided by Average Working Capital
Net profit ratio	Net Profit after Tax divided by Revenue from Operations
Return on equity ratio	Net Profit after Tax divided by Average net worth
Return on capital employed	EBIT divided by Capital Employed

8. Risk Factors

The following are the top 10 internal risk factors as disclosed in the RHP:

1. The operations in our Manufacturing Unit-1 had been suspended vide order No. V/T/MISC/20/2023/4790 dated August 23, 2023 by the Deputy Director and State Licensing Authority, Food and Drug Administration, Madhya Pradesh citing certain non-compliances.
2. We are dependent on a limited number of clients for a significant portion of our revenues, and the loss of any key client could adversely affect our business, financial condition and results of operations.
3. Any manufacturing or quality control problems may damage our reputation for high quality products and expose us to litigation or other liabilities, which could adversely affect our financial results.
4. The Company's manufacturing facilities are subject to inspections by the Central Drugs Standard Control Organisation (CDSCO), the State Licensing Authorities, and other competent regulatory bodies. Any adverse findings or non-compliance may result in regulatory actions that could adversely affect the Company's business, operations, and financial performance
5. We are dependent on third-party transportation providers for the supply of raw materials and finished products
6. Our inability to adopt new technologies could adversely affect our business, results of operations, cash flows and financial condition.
7. The Contracts in our order book may be adjusted, cancelled, or suspended by our clients at their discretion, and therefore our order book is not necessarily indicative of future revenues or earnings.
8. Our existing manufacturing facilities are concentrated in a single region i.e., Industrial Area, Indore, Madhya Pradesh and the inability to operate and grow our business in this particular region may have an adverse effect on our business, financial condition, results of operations, cash flows and future business prospects.
9. Our Company has negative cash flows from its investment and financing activities in the current and past years. Sustained negative cash flow could have an impact on our growth and business.
10. Our Company has had a high debt-to-equity ratio in previous financial years, and although this has improved in FY 2025, there can be no assurance that we will be able to maintain such levels going forward, which may affect our ability to meet obligations and pursue growth opportunities

For further details of the risks applicable to us, see “*Risk Factors*” beginning on page 21 of the Red Herring Prospectus. Investors are advised to read the risk factors carefully before making an investment decision in the Offer.

9. Details of weighted average cost of acquisition of Equity Shares of our Promoters (including our Promoter Selling Shareholders)

The weighted average cost of acquisition of Equity Shares of our Promoters (including our Promoter Selling Shareholders), are as follows:

Name	Number of Equity Shares of face value of Rs. 10	Weighted average cost of acquisition (“WACA”) of Equity Shares of face value of ₹ 10 each	WACA of Equity Shares face value of ₹ 10 each (in ₹ per Equity Share) acquired in last one year
Promoters			
Pradeep Mehta	44,44,816	Nil	Nil
Mukesh Mehta	44,44,725	Nil	Nil

For further details, see “*Capital Structure*” beginning on page 72 of the Red Herring Prospectus

10. Board of Directors and Key Managerial Personnel

The names and designations of members of the Board of Directors and Key Managerial Personnel are set forth below:

Sr. No	Name	Designation
Board of Directors		
1	Mr. Pradeep Mehta	Managing Director
2	Mr. Mukesh Mehta	Whole Time Director
3	Ms. Surabhi Mahajan	Director
4	Ms. Divya Khandelwal	Independent Director
5	Mr. Sumeet Bansal	Independent Director
Key Managerial Personnel		
6	Mr. Santosh Kale	Chief Financial Officer (CFO)
7	Ms. Pratiksha Bhandari	Company Secretary (CS)

For further details, see “*Our Management*” beginning on page 205 of the Red Herring Prospectus.

11. Auditor Qualifications

The Statutory Auditors of our Company have not expressed any qualification, reservation, adverse remark, matter of emphasis, or other observation on our financial statements for the periods covered in the Red Herring Prospectus.

For further details, please refer to the chapter titled “*Financial Statement as Restated*” on page 243 of the Red Herring Prospectus

12. Summary table of outstanding litigations

A summary of outstanding litigation proceedings involving our Company, Promoters, Directors, Key Managerial Personnel, members of Senior Management, and Subsidiaries as on the date of the Red Herring Prospectus in terms of the SEBI ICDR Regulations is provided below:

Name	By/Against	Civil Proceedings	Criminal Proceedings	Tax Proceedings	Actions by regulatory authorities	Amount Involved (in lakhs)
Company	By	Nil	Nil	NA	NA	Nil
	Against	Nil	Nil	09	01	4.30
Promoters	By	Nil	Nil	NA	NA	Nil
	Against	Nil	01	01	Nil	0.78
Group Companies/ Entities	By	Nil	Nil	NA	NA	Nil
	Against	Nil	Nil	01	Nil	0.14

Subsidiary	By	01	Nil	NA	NA	7.64
	Against	01	02	07	Nil	4.71
Directors otherthan promoters	By	Nil	Nil	NA	NA	Nil
	Against	Nil	Nil	Nil	Nil	Nil
Key Managerial Personnel and Senior Management	By	NA	Nil	NA	NA	Nil
	Against	NA	Nil	NA	Nil	Nil

For further details of the outstanding litigation proceedings, see “*Outstanding Litigation and Material Developments*” beginning on page 268.

The Equity Shares have not been and will not be registered under the U.S Securities Act of 1933, as amended (U.S. Securities Act) or any state securities laws in the United States and may not be offered or sold within the United States or to, or for the account or benefit of, U.S Persons (as defined in Regulation S), except pursuant to exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities laws. Accordingly, the Equity Shares are being offered and sold only outside the United States in offshore transaction in reliance on Regulation S under the U.S Securities Act and the applicable laws of the jurisdiction where those offers and sale occur. The Equity Shares have not been and will not be registered, listed or otherwise qualified in any other jurisdiction outside India and may not be offered or sold, and application may not be made by persons in any such jurisdiction, except in compliance with the applicable laws of such jurisdiction.

IN THE NATURE OF ABRIDGED PROSPECTUS - MEMORANDUM CONTAINING SALIENT FEATURES OF THE RED HERRING PROSPECTUS (RHP)

BIDDER'S UNDERTAKING AND CONFIRMATION FOR BID REVISION FORM

I/We (on behalf of joint Bidders, if any) confirm that the Acknowledgement Slip for my/our Bids is enclosed for the revisions which are being requested. I/We agree to be bound by all the terms & conditions mentioned in the Bid cum Application Form submitted earlier by me/us. I/We (on behalf of joint Bidders, if any) authorise you to reject this Bid Revision Form, in case any of the details of my/our exiting Bids as appearing on the electronic book building system do not tally with the details given in this Bid Revision Form.

INSTRUCTIONS FOR FILLING UP THE BID REVISION FORM

- Name of sole/ First Bidder should be exactly the same as it appears in the Depository records. In case of joint Bids, the Bid cum Application Form should contain only the name of the first Bidder whose name should also appear as the first holder of the beneficiary account held in joint names. The Bid means an "indication to make an offer" and not "an offer".
- Please ensure that the Bid options provided are in the same order as that provided in the Bid cum Application Form submitted earlier.
- In case there is no change in the particular Bid option, please write "NO CHANGE". In case you want to cancel the Bid option, please write "CANCELLED".
- Total Bid Amount payable must be calculated for the highest of three options, at Bid Price. Total Bid Amount to be paid must be calculated net of total amount paid at the time of submission of Bid cum Application Form. Bidders, please ensure that your bank has notified an SCSB Branch in the city where the Bid cum Application Form is being submitted.
- Revision of Bids in case of Revision of Price Band:** In case of an upward revision in the Price Band, Bidders who had Bid at Cut-off Price could either (i) revise their Bid or (ii) shall make additional payment based on the cap of the revised Price Band (such that the total amount i.e., original Bid Amount plus additional payment does not exceed ₹ 2,00,000 if the Bidder wants to continue to Bid at Cut-off Price), with the SCSBs/ members of the Syndicate/Registered Brokers /RTA/CDPs to whom the original Bid was submitted. In case the total amount (i.e., original Bid Amount plus additional payment) exceeds ₹ 2,00,000, the Bid will be considered for allocation under the Non-Institutional Portion in terms of the RHP or the Preliminary Offering Memorandum, as applicable. If, however, the Bidder does not either revise the Bid or make additional payment and the Issue Price is higher than the cap of the Price Band prior to revision, the number of Equity Shares Bid for, shall be adjusted downwards for the purpose of Allotment, such that no additional amount would be required to be blocked and the Bidder is deemed to have approved such revised Bid at Cut-off Price. In case of a downward revision in the Price Band, announced as above, UPI Bidders who have bid at Cut-off Price, could either revise their Bid or the excess amount blocked at the time of bidding would be unblocked from the ASBA Account after the Allotment is finalised.
- Only the First Bidder is required to sign the Bid cum Application Form /Revision Form. Thumb impressions and signatures other than in the languages specified in the Eighth Schedule to the Constitution of India must be attested by a Magistrate or a Notary Public or a Special Executive Magistrate under official seal. Applicants should specify only his/her ASBA bank account or UPI ID linked with his/her own bank account in case of sole Bidder and ASBA bank account or UPI ID linked with the bank account of First Bidder in case of joint Bidder, in the application form. If the First Bidder is not the account holder, ensure that the Bid cum Application Form is signed by the ASBA Account holder. Signature of the ASBA Account holder is mandatory.
- Please note that application made using third party UPI ID or third party ASBA Bank A/c are liable to be rejected.
 - QIBs cannot use UPI Mechanism to apply. Non-Institutional Bidders applying up to ₹ 5,00,000 can apply through UPI mode as per NPCI vide circular reference no. NPCI/UPI/OC No. 127/2021-22 dated December 09,2021 read with SEBI circular no. SEBI/HO/CFD/DIL2/CIR/P/2022/45 dated April 5, 2022.
 - UPI Bidders using UPI Mechanism:**
 - Please ensure that your bank is offering UPI facility for public offers.
 - Please mention UPI ID clearly in CAPITAL LETTERS only.
 - Ensure that the: (a) bank where the bank account linked to their UPI ID is maintained; and (b) Bidders Bidding using the UPI Mechanism may apply through the SCSBs and mobile applications whose names appears on the website of the SEBI (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=40>) and (<https://www.sebi.gov.in/sebiweb/other/OtherAction.do?doRecognisedFpi=yes&intmId=43>) respectively, as updated from time to time.
 - Eligible NRIs applying in the Issue through the UPI Mechanism, are advised to enquire with the relevant bank where their account is UPI linked prior to submitting their Bid cum Application Form.
 - UPI ID cannot exceed 45 characters.
 - Please ensure that you are using your UPI ID only and not the UPI ID of any third party.
 - UPI Bidders Bidding using the UPI Mechanism shall ensure that details of the Bid are reviewed and verified by opening the attachment in the UPI Mandate Request and then proceed to authorise the UPI Mandate Request using his/her UPI PIN. For further details, see "Issue Procedure" on page 311 of the RHP.
- Other Instructions:** a. Revision to Bids must be made only in the prescribed Revision Form, as applicable; b. Revision Form must be completed in fo i l, in BLOCK LETTERS in ENGLISH. Bidders should note that the Member of the Syndicate/ SCSBs/ Registered Brokers/RTA/CDPs will not be liable for errors in data entry due to incomplete or illegible Revision Forms; c. Ensure that Acknowledgment Slip for your Bid and any other applicable documents in support of the revision are attached with the Revision Form; and d. Bidders shall only be required to issue instruction to block the revised amount in excess of their original blocked amount based on the cap of the revised Price Band upon an upward revision of their Bid.
- Revision(s) in the Bid, the Bidders/Applicants will have to use the services of the same Designated Intermediary through which such Bidder/Applicant had placed the original Bid. Bidders/Applicants are advised to retain copies of the blank Revision Form and c the Bid(s) must be made only in such Revision Form or copies thereof Investors must ensure that their PAN is linked with Aadhaar card and are in compliance with the CBDT notification dated February 13,2020 and press release dated June 25,2021.

ISSUE STRUCTURE

Particulars of the Issue	Market Maker Reservation Portion	QIBs	Non - Institutional Investors	Individual Investor portion who applies for minimum application size
Number of Equity Shares available for allocation	1,89,000 Equity shares	36,000 Equity shares	17,55,000 Equity shares	17,92,000 Equity shares
Percentage of Issue Size available for allocation	5.01% of the issue size	Not more than 50.00% of the Net offer size shall be available for allocation to QIBs. However, 5.00% of net QIB Portion (excluding the Anchor Investor Portion) shall be available for allocation proportionately to Mutual Fund. Up to 60.00% of the QIB Portion may be available for allocation to Anchor Investors and 33.33% of the Anchor Investors Portion shall be allocation to domestic mutual funds and 6.67% for Life Insurance Companies (aggregating to 40%)	Not less than 15.00% of the Offer shall be available for allocation.	Not less than 35.00% shall be available for allocation.
Basis of Allotment	Firm Allotment	Proportionate as follows (excluding the Anchor Investor Portion: (a) up to 3,000 Equity Shares, shall be available for allocation on a proportionate basis to Mutual Funds only; and; (b) up to 36,000 Equity shares shall be allotted on a proportionate basis to all QIBs including Mutual Funds receiving allocation as per (a) above. For further details please refer to the section titled "Issue Procedure" beginning on page No. 311.	The allocation shall be as follows: (a) one third of the portion available to non-institutional investors shall be reserved for applicants with application size of more than two lots and up to such lots equivalent to not more than ₹10 lakhs; (b) two thirds of the portion available to non-institutional investors shall be reserved for applicants with application size of more than ₹10 lakhs.	Allotment to each Individual investor who applies for minimum application size shall not be less than 2 lots, subject to availability of Equity Shares in their Portion and the remaining available Equity Shares if any, shall be allotted on a proportionate basis. For details see, "Offer Procedure" on page No. 311.
Mode of Application	All the applicants shall make	the application (Online or Physical) through the ASBA P	rocess only (including UPI mechanism for Individual Investors using Syndicate ASBA).	
Minimum Bid Size	1,89,000 Equity Shares	Such number of Equity Shares and in multiples of 1,000 Equity Shares that the Bid Amount exceeds Rs.2,00,000	Such number of Equity Shares and in multiples of 1,000 Equity Shares that the Bid Amount exceeds Rs.2,00,000	2,000 Equity Shares in multiple of 1,000 Equity shares Constituting minimum 2 lots so that the Bid amount exceeds ₹ 2,00,000.
Maximum Application Size	1,89,000 Equity Shares	Such number of Equity Shares in multiples of 1,000 Equity Shares not exceeding the size of the Net Issue, subject to applicable limits.	Such number of Equity Shares in multiples of 1,000 Equity Shares not exceeding the size of the Net issue (excluding the QIB portion), subject to limits as applicable to the Bidder.	Such number of Equity Shares in multiples of 1,000 Equity Shares Constituting minimum 2 lots so that the Bid amount exceeds ₹ 2,00,000
Mode of Allotment			Dematerialized Form	
Trading Lot	1,000 Equity Shares, however, the Market Maker may accept odd lots if any in the market as required under the SEBI ICDR Regulations	1,000 Equity Shares and in multiples thereof	1,000 Equity Shares and in multiples thereof	1,000 Equity Shares and in multiples thereof
Terms of Payment	Full Bid Amount shall be blocked by the SCSBs in the bank account of the ASBA Bidder or by the Sponsor Bank through the UPI Mechanism that is specified in the ASBA Form at the time of submission of the ASBA Form.			

Note:

- In case of joint application, the Application Form should contain only the name of the First Applicant whose name should also appear as the first holder of the beneficiary account held in joint names. The signature of only such First Applicant would be required in the Application Form and such First Applicant would be deemed to have signed on behalf of the joint holders.
- Applicants will be required to confirm and will be deemed to have represented to our Company, the BRLM, their respective directors, officers, agents, affiliates, and representatives that they are eligible under applicable laws, rules, regulations, guidelines and approvals to acquire the Equity Shares in this Issue.
- SCSBs applying in the Issue must apply through an ASBA Account maintained with any other SCSB.

**COMMON BID CUM
REVISION FORM**

BIO MEDICA LABORATORIES LIMITED - INITIAL PUBLIC ISSUE - NR

Registered Office: Plot No. 11B-11C, Sector-E, Sanwer Road, Industrial Area, Industrial Estate (Indore), Indore,
Madhya Pradesh - 452015, India
Tel: +91 7314102751 Fax: N.A. Website: www.biomedica.co.in Email :companysecretary@biomedica.co.in
Company Secretary and Compliance Officer: Ms. Pratiksha Bhandari CIN: U24230MP2015PLC034576

FOR NON-RESIDENTS, INCLUDING ELIGIBLE NRIs, FPIs,
FVCIs AND REGISTERED MULTI LATERAL AND
BILATERAL DEVELOPMENT FINANCIAL INSTITUTIONS
ETC. APPLYING ON A REPATRIATION BASIS



To,
The Board of Directors

BIO MEDICA LABORATORIES LIMITED

100% BOOK BUILT ISSUE

ISIN: INE1BKA01015

**Bid cum
Application
Form No.**

MEMBERS OF THE SYNDICATE STAMP & CODE

SUB-SYNDICATE MEMBER/ REGISTERED BROKER
SCSB/CDP/RTA STAMP & CODE

SUB-BROKER'S / SUB-AGENT'S STAMP &

SCSB BRANCH STAMP & CODE

BANK BRANCH SERIAL NO.

SCSB SERIAL NO.

1. NAME & CONTACT DETAILS OF SOLE / FIRST BIDDER

Mr./Ms./M/s. _____

Address _____

Email _____

Tel. No.(with STD code)/Mobile _____

2. PAN OF SOLE / FIRST BIDDER

3. BIDDER'S DEPOSITORY ACCOUNT DETAILS ☐ NSDL ☐ CDSL

For NSDL enter 8 digit DP ID followed by 8 digit Client ID / For CDSL enter 16 digit Client ID

PLEASE CHANGE MY BID

4. FORM (AS PER LAST BID OR REVISION)

Bid Options	No. of Equity Shares Bid (In Figures) (Bids must be in multiples of 1,000 Equity Shares)								Price per Equity Share (₹)/ “Cut-off” (Price in multiples of ₹ 1/- only)											
									(In Figures only)											
	(In Figures)								Bid Price			Retail Discount			Net Price			“Cut-off” (Please ✓ tick)		
	8	7	6	5	4	3	2	1	3	2	1	3	2	1	3	2	1			
Option 1																		<input type="checkbox"/>		
(OR) Option 2																		<input type="checkbox"/>		
(OR) Option 3																		<input type="checkbox"/>		

5. TO (REVISED BID) (ONLY INDIVIDUAL BIDDERS CAN BID AT "CUT-OFF")

Bid Options	No. of Equity Shares Bid (In Figures) (Bids must be in multiples of 1,000 Equity Shares)								Price per Equity Share (₹)/ “Cut-off” (Price in multiples of ₹ 1/- only)											
									(In Figures only)											
	(In Figures)								Bid Price			Retail Discount			Net Price			“Cut-off” (Please ✓ tick)		
	8	7	6	5	4	3	2	1	3	2	1	3	2	1	3	2	1			
Option 1																		<input type="checkbox"/>		
(OR) Option 2																		<input type="checkbox"/>		
(OR) Option 3																		<input type="checkbox"/>		

Please note that applications must be made in minimum of 2,000 Equity Shares and further multiples of 1,000 Equity Shares accordingly.

6. PAYMENT DETAILS [IN CAPITAL LETTERS]

PAYMENT OPTION : FULL PAYMENT ☒

Amount blocked(₹ in figures) _____ (₹ in words) _____

ASBA Bank A/c No. _____

Bank Name & Branch _____

OR

UPI ID(Maximum 45 characters) _____

I/WE (ON BEHALF OF JOINT BIDDERS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ AND UNDERSTOOD THE TERMS AND CONDITIONS OF THIS COMMON BID CUM APPLICATION FORM, THE ATTACHED ABRIDGED PROSPECTUS AND THE GENERAL INFORMATION DOCUMENT ("GID") FOR INVESTING IN PUBLIC ISSUES AND HEREBY AGREE AND CONFIRM THE "BIDDER'S UNDER TAKING" AS GIVEN OVERLEAF. I/WE (ON BEHALF OF JOINT BIDDERS, IF ANY) HEREBY CONFIRM THAT I/WE HAVE READ THE INSTRUCTIONS FOR FILLING UP THE BID CUM APPLICATION FORM GIVEN OVERLEAF.

7A. SIGNATURE OF SOLE/ FRIST BIDDER

**7B. SIGNATURE OF ASBA BANK ACCOUNT HOLDER(s)
(AS PER BANK RECORDS)**

I/We authorise the SCSB to do all acts as are necessary to make the application in the Offer.

- 1) _____
2) _____
3) _____

Date: _____, 2026

MEMBERS OF THE SYNDICATE / SUB-SYNDICATE
MEMBER / REGISTERED BROKER / SCSB / CDP /
RTA / AGENT STAMP (Acknowledging upload of
Bid in Stock Exchange system)

TEAR HERE



Bio Medica Laboratories

**BIO MEDICA LABORATORIES
LIMITED**

BID REVISION FORM-INITIAL PUBLIC ISSUE-NR

**Acknowledgement Slip for Members
of the Syndicate / Sub-Syndicate
Member / Registered Broker / SCSB /
CDP / RTA / Agent**

**Bid cum
Application
Form No.**

PAN of Sole / First Bidder

DP ID/
CL ID _____

Additional Amount Blocked (₹ in figures) _____

ASBA Bank A/c No./UPI ID _____

Stamp & Signature of SCSB Branch

Bank Name & Branch _____

Received from Mr./Ms./M/s. _____

Telephone / Mobile _____ Email _____

TEAR HERE

**BIO MEDICA LABORATORIES
LIMITED
INITIAL PUBLIC ISSUE - NR**

	Option 1	Option 2	Option 3
No. of Equity Shares			
Bid Price (₹)			
Additional Amount Blocked (₹ in figures)			

Stamp & Signature of Members of the Syndicate / Sub-Syndicate
Member / Registered Broker / SCSB / CDP / RTA / Agent

Name of Sole / First Bidder

Acknowledgement Slip for Bidder

**Bid cum
Application
Form No.**

ASBA Bank A/c No./UPI ID _____

Bank Name & Branch _____

Important Note: Application made using third party UPI ID or ASBA Bank A/c are liable to be rejected.